CN1876097A - 治疗妇女更年期综合症改进的中药胶囊 - Google Patents
治疗妇女更年期综合症改进的中药胶囊 Download PDFInfo
- Publication number
- CN1876097A CN1876097A CN 200610076259 CN200610076259A CN1876097A CN 1876097 A CN1876097 A CN 1876097A CN 200610076259 CN200610076259 CN 200610076259 CN 200610076259 A CN200610076259 A CN 200610076259A CN 1876097 A CN1876097 A CN 1876097A
- Authority
- CN
- China
- Prior art keywords
- chinese medicinal
- radix
- volatile oil
- medicinal capsule
- capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 76
- 208000011580 syndromic disease Diseases 0.000 title claims description 47
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 32
- 239000000314 lubricant Substances 0.000 claims abstract description 7
- 239000011230 binding agent Substances 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 61
- 238000000605 extraction Methods 0.000 claims description 54
- 239000000341 volatile oil Substances 0.000 claims description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 29
- 239000000843 powder Substances 0.000 claims description 29
- 239000000243 solution Substances 0.000 claims description 23
- 239000000284 extract Substances 0.000 claims description 21
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 20
- 239000000706 filtrate Substances 0.000 claims description 20
- 241000208340 Araliaceae Species 0.000 claims description 19
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 19
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 19
- 235000008434 ginseng Nutrition 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 19
- 238000001035 drying Methods 0.000 claims description 16
- 229920002472 Starch Polymers 0.000 claims description 13
- 239000002671 adjuvant Substances 0.000 claims description 13
- 239000008107 starch Substances 0.000 claims description 13
- 235000019698 starch Nutrition 0.000 claims description 13
- 229920000858 Cyclodextrin Polymers 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 12
- 238000005469 granulation Methods 0.000 claims description 12
- 230000003179 granulation Effects 0.000 claims description 12
- 239000001116 FEMA 4028 Substances 0.000 claims description 11
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 11
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 11
- 229960004853 betadex Drugs 0.000 claims description 11
- 238000004821 distillation Methods 0.000 claims description 10
- 238000002481 ethanol extraction Methods 0.000 claims description 9
- 239000003921 oil Substances 0.000 claims description 9
- 238000005303 weighing Methods 0.000 claims description 9
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- 239000012047 saturated solution Substances 0.000 claims description 8
- 210000000582 semen Anatomy 0.000 claims description 8
- 239000012567 medical material Substances 0.000 claims description 7
- 239000006228 supernatant Substances 0.000 claims description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 229950005162 benexate Drugs 0.000 claims description 6
- IAXUQWSLRKIRFR-SAABIXHNSA-N chembl2104696 Chemical compound C1C[C@@H](CNC(=N)N)CC[C@@H]1C(=O)OC1=CC=CC=C1C(=O)OCC1=CC=CC=C1 IAXUQWSLRKIRFR-SAABIXHNSA-N 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 6
- 239000003230 hygroscopic agent Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 229920006395 saturated elastomer Polymers 0.000 claims description 6
- 239000000741 silica gel Substances 0.000 claims description 6
- 229910002027 silica gel Inorganic materials 0.000 claims description 6
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 4
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 238000010790 dilution Methods 0.000 claims description 4
- 239000012895 dilution Substances 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000003208 petroleum Substances 0.000 claims description 4
- 238000004062 sedimentation Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 3
- 230000001070 adhesive effect Effects 0.000 claims description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 3
- 229960004756 ethanol Drugs 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 abstract description 14
- 239000000463 material Substances 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 abstract description 3
- 235000013399 edible fruits Nutrition 0.000 abstract 3
- 244000001632 Acorus gramineus Species 0.000 abstract 1
- 235000013073 Acorus gramineus Nutrition 0.000 abstract 1
- 241000605447 Anemarrhena Species 0.000 abstract 1
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 235000011202 Angiopteris lygodiifolia Nutrition 0.000 abstract 1
- 241000212948 Cnidium Species 0.000 abstract 1
- 241000759833 Cornus officinalis Species 0.000 abstract 1
- 240000007371 Cuscuta campestris Species 0.000 abstract 1
- 241000723185 Cyathea Species 0.000 abstract 1
- 241000157491 Morinda Species 0.000 abstract 1
- 240000005001 Paeonia suffruticosa Species 0.000 abstract 1
- 235000003889 Paeonia suffruticosa Nutrition 0.000 abstract 1
- 241000208966 Polygala Species 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 244000197580 Poria cocos Species 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 240000006079 Schisandra chinensis Species 0.000 abstract 1
- 235000008422 Schisandra chinensis Nutrition 0.000 abstract 1
- 244000299492 Thespesia populnea Species 0.000 abstract 1
- 235000009430 Thespesia populnea Nutrition 0.000 abstract 1
- 229930191283 anemarrhena Natural products 0.000 abstract 1
- 239000004067 bulking agent Substances 0.000 abstract 1
- 239000002274 desiccant Substances 0.000 abstract 1
- 235000017524 noni Nutrition 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 14
- 230000008569 process Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 8
- 239000008187 granular material Substances 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 238000003809 water extraction Methods 0.000 description 6
- 239000000470 constituent Substances 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000009245 menopause Effects 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 210000001215 vagina Anatomy 0.000 description 3
- TZJALUIVHRYQQB-XFDQAQKOSA-N Icariin Natural products O(C)c1ccc(C2=C(O[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(C/C=C(\C)/C)c3O2)cc1 TZJALUIVHRYQQB-XFDQAQKOSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- TZJALUIVHRYQQB-XLRXWWTNSA-N icariin Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-XLRXWWTNSA-N 0.000 description 2
- TZJALUIVHRYQQB-UHFFFAOYSA-N icariine Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(C)O2)O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-UHFFFAOYSA-N 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010024419 Libido decreased Diseases 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- HPUXDMUGCAWDFW-UHFFFAOYSA-N Osthole Natural products COc1ccc2CCC(=O)Oc2c1C=CC(=O)C HPUXDMUGCAWDFW-UHFFFAOYSA-N 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- -1 lignanoid Chemical compound 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- MBRLOUHOWLUMFF-UHFFFAOYSA-N osthole Chemical compound C1=CC(=O)OC2=C(CC=C(C)C)C(OC)=CC=C21 MBRLOUHOWLUMFF-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
水平 | 因素 | |||
加水量(倍) | 浸泡时间(h) | 蒸馏时间(h) | 空白 | |
123 | 6810 | 0.02.04.0 | 456 |
水平 | 因素 | |||
乙醇浓度 | 加醇量(倍) | 浸提时间(h) | 提取次数 | |
123 | 80%70%60% | 12108 | 1.51.00.5 | 321 |
水平 | 因素 | |||
加水量(倍) | 浸提时间(h) | 提取次数 | 空白 | |
123 | 1086 | 2.01.51.0 | 321 |
批次 | 投药量 | 出粉率 | β-环糊精包合物量 | CaCO3量 | 收膏量 | 总出粉量 |
010203 | 973g973g973g | 905g895g900g | 133g139g134g | 422g426g424g | 2110g2130g2120g | 3570g3590g3578g |
辅料种类 | 淀粉 | CaCO3 | 糊精 |
结果 | 不易吸湿 | 不易吸湿 | 易吸湿 |
流动性好 | 流动性好 | 流动性较差 |
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200610076259XA CN100488544C (zh) | 2006-04-21 | 2006-04-21 | 一种改进的治疗妇女更年期综合症的中药胶囊 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200610076259XA CN100488544C (zh) | 2006-04-21 | 2006-04-21 | 一种改进的治疗妇女更年期综合症的中药胶囊 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1876097A true CN1876097A (zh) | 2006-12-13 |
CN100488544C CN100488544C (zh) | 2009-05-20 |
Family
ID=37508766
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB200610076259XA Expired - Fee Related CN100488544C (zh) | 2006-04-21 | 2006-04-21 | 一种改进的治疗妇女更年期综合症的中药胶囊 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100488544C (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101366903B (zh) * | 2008-08-27 | 2011-02-16 | 王素芹 | 一种治疗更年期综合症的中药组合物 |
CN102526385A (zh) * | 2012-01-17 | 2012-07-04 | 丁敏 | 一种治疗更年期综合征的药剂 |
CN105999124A (zh) * | 2016-07-29 | 2016-10-12 | 张玮玮 | 一种治疗围绝经期综合征的中药制剂及制备方法 |
CN107334977A (zh) * | 2017-06-20 | 2017-11-10 | 苏州市李良济健康产业有限公司 | 一种防治更年期综合症的保健品的制备方法 |
-
2006
- 2006-04-21 CN CNB200610076259XA patent/CN100488544C/zh not_active Expired - Fee Related
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101366903B (zh) * | 2008-08-27 | 2011-02-16 | 王素芹 | 一种治疗更年期综合症的中药组合物 |
CN102526385A (zh) * | 2012-01-17 | 2012-07-04 | 丁敏 | 一种治疗更年期综合征的药剂 |
CN105999124A (zh) * | 2016-07-29 | 2016-10-12 | 张玮玮 | 一种治疗围绝经期综合征的中药制剂及制备方法 |
CN107334977A (zh) * | 2017-06-20 | 2017-11-10 | 苏州市李良济健康产业有限公司 | 一种防治更年期综合症的保健品的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN100488544C (zh) | 2009-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1876096A (zh) | 治疗妇女更年期综合症中药胶囊主药组分及其制备方法 | |
CN1876097A (zh) | 治疗妇女更年期综合症改进的中药胶囊 | |
CN1615958A (zh) | 用于治疗中风和胸痹的中药制剂及其制备方法 | |
CN1850234A (zh) | 妇宁康薄膜衣片及其制备方法 | |
CN1899590A (zh) | 舒肝清热、健脾养血的妇科中成药及其制备方法 | |
CN1421241A (zh) | 一种治疗心脑血管疾病的复方丹参滴丸及其制备方法 | |
CN1055227C (zh) | 一种治疗男性不育症的药物及制备方法 | |
CN1850253A (zh) | 千金保孕制剂及新的制备方法 | |
CN1814021A (zh) | 血府逐瘀膏剂及其制备方法 | |
CN1421239A (zh) | 一种治疗心脑血管疾病的复方丹参制剂及其制备方法 | |
CN106421630A (zh) | 一种郁金提取物及其制备方法和应用 | |
CN1305487C (zh) | 治疗良性前列腺增生症引起排尿障碍的药物组合物及其制法 | |
CN1850241A (zh) | 维c银翘分散片及其制备方法 | |
CN1733104A (zh) | 治疗妇科疾病的桂枝茯苓制剂及其制备方法和应用 | |
CN1850248A (zh) | 一种治疗乳腺增生的中药胶囊及其制备方法 | |
CN1775258A (zh) | 暖宫孕子制剂及新的制备方法 | |
CN1709300A (zh) | 治疗骨质疏松症的仙灵骨葆软胶囊及制备方法 | |
CN1872232A (zh) | 治疗脑血管疾病的药物组合物及其制备方法 | |
CN101036709A (zh) | 一种用于治疗妇科疾病的中药制剂及其制备方法 | |
CN1583133A (zh) | 一种治疗骨科疾病的泡腾片及其制备方法 | |
CN1319519C (zh) | 一种治疗心脑血管疾病的复方丹参喷雾剂 | |
CN1319521C (zh) | 一种治疗心脑血管疾病的复方丹参颗粒 | |
CN1628763A (zh) | 治疗妇科疾病的桂枝茯苓制剂及其制备方法 | |
CN1748764A (zh) | 调经促孕制剂及新的制备方法 | |
CN1872250A (zh) | 一种治疗头痛的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Taiyangshi (Tangshan) Pharm Ind Co., Ltd. Assignor: Han Zhiqiang Contract fulfillment period: 2007.09.05 to 2015.06.22 Contract record no.: 2007990000037 Denomination of invention: Improved Chinese medicine capsule for treating women's menopausal syndrome Granted publication date: unauthorized License type: Exclusive license Record date: 20070912 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENCE; TIME LIMIT OF IMPLEMENTING CONTACT: 2007.9.5 TO 2015.6.22 Name of requester: TAIYANGSHI (TANGSHAN) PHARMACEUTICAL CO. LTD. Effective date: 20070912 |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Taiyangshi (Tangshan) Pharm Ind Co., Ltd. Assignor: Han Zhiqiang Contract fulfillment period: 2009.10.20 to 2014.10.19 Contract record no.: 2009990001300 Denomination of invention: Improved Chinese medicine capsule for treating climacteric syndrome of women Granted publication date: 20090520 License type: General permission Record date: 20091130 Assignee: Taiyangshi (Tangshan) Pharm Ind Co., Ltd. Assignor: Han Zhiqiang Contract fulfillment period: 2009.12.16 to 2026.5.30 Contract record no.: 2009990001331 Denomination of invention: Improved Chinese medicine capsule for treating climacteric syndrome of women Granted publication date: 20090520 License type: Exclusive license Record date: 20091217 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: COMMON LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2009.10.20 TO 2014.10.19; CHANGE OF CONTRACT Name of requester: TAIYANGSHI (TANGSHAN) PHARMACEUTICAL CO. LTD. Effective date: 20091130 Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2009.12.16 TO 2026.5.30; CHANGE OF CONTRACT Name of requester: TAIYANGSHI (TANGSHAN) PHARMACEUTICAL CO. LTD. Effective date: 20091217 |
|
ASS | Succession or assignment of patent right |
Owner name: SUNSTONE (TANGSHAN) PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: HAN ZHIQIANG Effective date: 20101123 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 063020 HUOJU ROAD, HIGH-TECH. DEVELOPMENT AREA, TANGSHAN CITY, HEBEI PROVINCE TO: 063020 NO. 139, HUOJU ROAD, HIGH-TECH. DEVELOPMENT AREA, TANGSHAN CITY, HEBEI PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20101123 Address after: 063020 Torch Road, Tangshan City hi tech Development Zone, Hebei 139, China Patentee after: Taiyangshi (Tangshan) Pharm Ind Co., Ltd. Address before: 063020 Torch Road, Tangshan City hi tech Development Zone, Hebei Patentee before: Han Zhiqiang |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090520 Termination date: 20200421 |